Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Respiratory Viral Infection Assay Service

Online Inquiry

Background Service Workflow Advantages Case Study FAQs

Patients undergoing advanced cellular immunotherapies, such as those involving CD19-targeted chimeric antigen receptor (CAR)–modified T cells, B-cell maturation antigen (BCMA)–targeted CAR T cells, and natural killer cells, face a heightened risk of severe respiratory viral infections (RVIs), leading to increased morbidity and mortality. Creative Biolabs provides a respiratory viral infection assay service that aims to address critical challenges in this field, such as long diagnostic cycles, difficulties in identifying precise viral strains, complexities in evaluating antiviral efficacy, and the intricate demands of clinical trials for respiratory diseases.

The Necessity for Respiratory Viral Infection Assay

Respiratory viral infections, including influenza, respiratory syncytial virus (RSV), and SARS-CoV-2, represent a persistent global health challenge, causing significant morbidity and mortality across all demographics, particularly in immunocompromised individuals. The dynamic nature of these viruses, characterized by rapid evolution and the emergence of new strains, necessitates continuous innovation in diagnostic and research tools. Precise and prompt identification of particular viral viruses is essential for public health initiatives, clinical care, and co-infection distinction. Furthermore, robust assay services are indispensable for the discovery and development of novel antiviral therapeutics and vaccines, enabling precise evaluation of viral kinetics and host immune responses.

Fig.1 Infections after CD19 CAR T cell therapy. (OA Literature) Fig.1 Infections following CD19 CAR T cell treatment.¹

Respiratory Viral Infection Assay Service at Creative Biolabs

Creative Biolabs' respiratory viral infection assay service provides comprehensive solutions designed to meet the rigorous demands of antiviral drug discovery, vaccine development, and clinical research. Our workflow is meticulously designed to ensure high-quality results and clear, actionable insights, providing a streamlined path for your research and development needs. We deliver precise, reliable data crucial for advancing your projects, from early-stage screening to preclinical evaluation.

Workflow

Step 1

Project Consultation & Design

We begin with an in-depth discussion to understand your specific research objectives, target viruses, sample types, and desired assay requirements. This collaborative approach ensures the development of a tailored assay strategy.

Step 2

Sample Preparation & Quality Control

Rigorous preparation of your provided samples is paramount. This includes nucleic acid extraction, viral particle quantification, and comprehensive sample integrity checks to ensure optimal assay performance.

Step 3

Assay Execution

Our expert team performs the chosen assays using state-of-the-art platforms. This may include quantitative PCR (qPCR) for viral load, ELISA for antibody detection, cytopathic effect (CPE) assays, plaque assays for viral infectivity, or neutralization assays for antiviral efficacy.

Step 4

Data Analysis & Interpretation

Raw data undergoes thorough statistical analysis, data visualization, and comparison against established controls and standards. Our bioinformaticians and virologists interpret the results in the context of your project goals.

Step 5

Reporting & Consultation

We provide a comprehensive, detailed experimental report summarizing methodologies, raw data, analyzed results, and our expert interpretations. A follow-up consultation is arranged to discuss the findings and recommend next steps.

Our Service Advantages

High Sensitivity and Specificity: Ensures accurate viral detection and quantification.
Rapid Turnaround Times: Essential for time-sensitive projects.
Flexible Platforms: Adaptable to a wide range of respiratory viruses and sample types, ensuring comprehensive coverage.
Reliable, Reproducible Results: Delivered through advanced technologies and expert scientific oversight, crucial for preclinical and clinical development.
Accelerated Project Timelines: Direct translation of benefits into faster project completion.
Reduced Research Costs: Optimized processes lead to more cost-effective research.

Case Study

Case Study One:

Through our Respiratory Viral Infection Assay Service, a leading pharmaceutical company successfully identified multiple novel antiviral compounds against influenza within a significantly reduced timeframe, accelerating their preclinical development. Our high-throughput screening assays enabled rapid evaluation of compound libraries, leading to the prioritization of promising candidates.

Case Study Two:

After using our Respiratory Viral Infection Assay Service, a prominent academic research institution successfully completed a large-scale seroprevalence study for RSV, providing critical epidemiological data for public health initiatives. Our robust immunoassay platforms ensured accurate and reproducible results across thousands of samples, contributing to a deeper understanding of RSV transmission dynamics.

FAQs

Q1: What types of respiratory viruses can your assays detect?

A1: Our service is designed to detect a broad spectrum of respiratory viruses, including but not limited to Influenza A/B, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), parainfluenza viruses (PIV), rhinoviruses, adenoviruses, and various coronaviruses including SARS-CoV-2. If you have a specific viral target, please inquire, and we can discuss custom assay development.

Q2: Can your service be adapted for high-throughput screening of antiviral compounds?

A2: Our systems are extremely versatile for high-throughput screening. We can develop customized assays to screen large libraries of compounds for antiviral activity against your target respiratory virus, providing critical data for lead compound identification and optimization.

Related Services

After CAR-T cell therapy, patients can be vulnerable to a range of infections beyond just respiratory viruses. We offer comprehensive infectious disease assays targeting a wide array of microorganisms that pose a risk to these immunocompromised patients. Our services include:

For more details about our respiratory viral infection assay service, please don't hesitate to get in touch with us.

Reference

Wudhikarn, Kitsada et al. "Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma." Blood cancer journal vol. 10,8 79. 5 Aug. 2020, doi:10.1038/s41408-020-00346-7. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.